Genetically engineered mice provide powerful tools for understanding mammalian gene function. These models traditionally rely on gene overexpression from transgenes or targeted, irreversible gene mutation. By adapting the tetracycline (tet)-responsive system previously used for gene overexpression, we have developed a simple transgenic system to reversibly control endogenous gene expression using RNA interference (RNAi) in mice. Transgenic mice harboring a tet-responsive RNA polymerase II promoter driving a microRNA-based short hairpin RNA targeting the tumor suppressor Trp53 reversibly express short hairpin RNA when crossed with existing mouse strains expressing general or tissue-specific 'tet-on' or 'tet-off' transactivators. Reversible Trp53 knockdown can be achieved in several tissues, and restoring Trp53 expression in lymphomas whose development is promoted by Trp53 knockdown leads to tumor regression. By leaving the target gene unaltered, this approach permits tissue-specific, reversible regulation of endogenous gene expression in vivo, with potential broad application in basic biology and drug target validation.
Mouse models are powerful tools for studying gene function in mammalian systems. Through transgenesis and homologous recombination, the mouse genome can be manipulated to bring about heritable, tissue-specific and reversible overexpression of proteincoding cDNAs, disruption of single genes and knock-in of mutant alleles 1 . Conditional gene inactivation can also be achieved using sitespecific recombination systems, including Cre/loxP and Flp/FRT 2 . As recombinase activity in these transgenic systems can be controlled temporally and spatially, they have been particularly useful for studying the adult function of genes that are essential for mouse development 3 . Furthermore, acute disruption of gene function can circumvent genetic compensatory mechanisms inherent to germline mutant models 4 .
Despite their utility, recombination-based systems for conditional gene inactivation in mice have limitations: the crossing strategies to generate these models are time consuming, recombinase expression can be genotoxic 5 and, most notably, recombination disrupts the target locus irreversibly. In many experimental contexts, such as studying gene function during mouse development or mimicking effects of potential targeted therapeutics in mouse models of human disease 6 , transient and/or tissue-specific inhibition of endogenous genes is desirable.
Tet-regulated gene overexpression systems were initially developed for use in cultured cells 7 , but they are also effective in transgenic mice 8 . Regulated transcription from the tet-responsive TRE promoter relies on the activity of a tet transactivator protein, which can be either activated ('tet-on') or repressed ('tet-off') by tetracycline or its analog doxycycline. Expressing tet transactivators from tissue-specific promoters 9 allows spatial and temporal control of gene overexpression, a strategy widely used to study mouse embryonic and postnatal development 10, 11 and oncogene addiction 12 . Hence, many mouse lines have been developed that express the tTA (tet-off) or rtTA (tet-on) transactivators in different cell types.
RNAi holds great promise as an experimental tool for loss-offunction genetics. In many cell-based systems, short hairpin RNAs (shRNAs) have been expressed from tet-responsive or Cre/loxPregulated promoters, allowing reversible gene inhibition 13 . Recent studies indicate that ubiquitous 14 or tissue-specific 15 RNA polymerase II promoters can be used to express microRNA-based shRNAs in transgenic animals, and other transgenic models have used Cre/loxPmediated excision or activation of RNA polymerase III promoters to control shRNA expression unidirectionally [16] [17] [18] [19] . However, these approaches do not fully exploit a major experimental advantage of RNAi: in principle, its effects can be tissue specific and reversible.
The aim of this study was to determine whether RNAi can be used as a tool to reversibly regulate expression of an endogenous gene in mice. We and others recently showed that RNA polymerase II promoters, including the tet-responsive TRE promoter, can be used to express shRNAs based on microRNA precursors 20, 21 . This raised the possibility that the tet-regulated expression system, used thus far for cDNA overexpression in mice, could be exploited to reversibly inhibit gene expression in vivo. Here we create a transgenic mouse line harboring a tet-regulated shRNA cassette whose expression can be regulated in a tissue-specific manner when crossed with existing tet transactivator mouse strains. Using this system, we demonstrate reversible Trp53 knockdown in several adult tissues, and we examine the impact of restoring Trp53 expression in tumors driven by attenuated Trp53 function. Our results establish proof of principle for a transgenic RNAi technology that may eventually be used to spatially, temporally and reversibly regulate the expression of any endogenous gene.
RESULTS
Mimicking strategies used previously for tet-regulated gene overexpression in mice, we generated a transgene comprising the tetresponsive TRE-CMV promoter 7 upstream of a shRNA targeting mouse Trp53 referred to as p53.1224 (ref. 20) (Fig. 1a) . We generated several founder lines harboring the TRE-p53.1224 transgene using standard pronuclear injection procedures 22 . To test each line for its ability to express the Trp53 shRNA from the TRE promoter, we isolated transgenic mouse embryonic fibroblasts (MEFs) and infected them with a retrovirus expressing tTA (tet-off), which transactivates the TRE promoter in the absence of doxycycline. Of nine TRE-p53.1224 founder lines tested, two (A and D) showed marked, tTA-dependent Trp53 knockdown in MEFs (Fig. 1b,c) doxycycline (Fig. 1d) . Unless otherwise indicated, we present results obtained using founder line A; however, line D behaved similarly in each context tested.
Consistent with the known effects of Trp53 deficiency, transgenic MEFs expressing tTA formed colonies when plated at low density but grew similarly to wild-type MEFs in the presence of doxycycline (Fig. 1e) . Thus, in these founder lines, the TRE-p53.1224 transgenes are integrated at genomic locations conducive to reversible regulation by a tet transactivator. We observed similar tTA-dependent gene knockdown in MEFs isolated from a single transgenic line (of four tested) harboring a TRE-p16/p19.478 transgene ( Supplementary Fig. 1 online) . In this case, the shRNA is designed to target the transcript that encodes both p19 ARF and p16 INK4a , verifying that genes other than Trp53 can be targeted with this approach.
The rtTA (tet-on) transactivator is expressed in MEFs derived from Rosa26-rtTA transgenic embryos 11 . To test whether the amount of rtTA produced by the Rosa26-rtTA transgene was sufficient to drive effective shRNA expression, we cultured MEFs derived from a cross between TRE-p53.1224 and Rosa26-rtTA mice. We observed substantial Trp53 knockdown upon doxycycline treatment of Rosa26-rtTA/ TRE-p53.1224 'double-transgenic' MEFs ( Fig. 2a) , and Trp53 expression was restored with similar kinetics after doxycycline withdrawal (Fig. 2b) . We observed functional Trp53 knockdown in Rosa26-rtTA/ TRE-p53.1224 MEFs isolated using founder lines A and D (Fig. 2c-e ) and in double-transgenic MEFs isolated from a cross between TREp53.1224 and a different general tet-on mouse strain, CMV-rtTA 23 ( Fig. 2f,g ). These results demonstrate that effective and reversible knockdown of an endogenous gene can be achieved in an entirely transgenic setting.
The Rosa26-rtTA and CMV-rtTA mouse lines have been used previously to regulate tet-on cDNA overexpression in tissues of adult mice 11, 23 . To test whether they could also drive shRNA expression in these tissues, we measured p53.1224 short interfering RNA (siRNA) production in adult organs of doxycycline-treated Rosa26-rtTA/TRE-p53.1224 and CMV-rtTA/TRE-p53.1224 mice. Though we were unable to detect siRNA production in Rosa26-rtTA/TREp53.1224 tissues (data not shown), several tissues from CMV-rtTA/ TRE-p53.1224 mice contained abundant siRNA, consistent with the known expression pattern of the CMV promoter (Fig. 3a) . p53.1224 siRNA production was doxycycline dependent (Fig. 3b) and, in tissues such as muscle and skin, was of similar abundance as in positive control tumor samples in which Trp53 knockdown is required for tumor maintenance (Fig. 3c) .
To test Trp53 knockdown in adult tissues, we subjected doxycyclinetreated CMV-rtTA/TRE-p53.1224 mice to whole-body ionizing radiation (which induces Trp53 in some tissues 24 ) and examined Trp53 levels by immunohistochemistry or immunoblotting of cell lysates. Radiation-induced Trp53 expression was substantially reduced in the basal layer of the esophageal epithelium of doxycycline-treated mice (Fig. 3d) . Furthermore, we observed a marked reduction in radiationinduced apoptosis in the thymus of doxycycline-treated CMV-rtTA/ TRE-p53.1224 mice compared with their single transgenic littermates ( Fig. 4a) and also in cultured thymocytes derived from these mice, in which Trp53 protein level was clearly reduced after radiation treatment (Fig. 4b,c and Supplementary Fig. 2 online) . Together, these results indicate that doxycycline-dependent Trp53 shRNA expression in thymocytes of adult CMV-rtTA/TRE-p53.1224 mice is sufficient to protect them from an apoptotic stimulus in vivo.
Tissue-specific control of transgene expression using tetracyclinebased systems has proven to be effective for studying the impact of gene overexpression in particular tissues. To test whether p53.1224 siRNA expression could be similarly restricted to a particular tissue in adult mice, we crossed TRE-p53.1224 mice with LAP-tTA transgenic mice 9 . In these mice, the liver-enriched transcriptional activator protein (LAP; also known as C/EBPb) promoter drives expression of the tTA (tet-off) protein specifically in differentiated hepatocytes. As predicted, we detected Trp53 siRNA only in the liver of adult LAPtTA/TRE-p53.1224 mice (Fig. 5a) . siRNA production was inhibited by addition of doxycycline to the drinking water, with no effect on the levels of the endogenous liver-specific microRNA miR-122 (ref. 5b) . We observed similar tissue-specific siRNA expression in LAP-tTA/TRE-p53.1224 line D mice ( Supplementary Fig. 3 online).
To test whether this level of siRNA production was sufficient to affect Trp53 expression, we injected mice with recombinant adenovirus, which is known to localize to the liver and induce Trp53 protein 26 (an alternative to radiation, which does not induce Trp53 in the liver 24 ).
Immunofluorescence showed a substantial reduction in Trp53 levels in livers of LAP-tTA/TRE-p53.1224 mice but not in doxycycline-treated animals ( Fig. 5c) . Thus, tet transactivator strains previously designed for tissue-specific gene overexpression can also drive reversible gene knockdown in specific organs. We also tested whether tissue-specific expression of the p53.1224 shRNA from the transgenic TRE promoter was sufficient to inhibit Trp53 function in vivo. To this end, we used a well-characterized model in which Trp53 loss promotes tumorigenesis: the Em-Myc transgenic mouse. These animals express the Myc oncogene in B cells and develop pre-B or B cell lymphoma 27 . Em-Myc lymphomagenesis is markedly accelerated by Trp53 deficiency 28, 29 or after reconstitution of lethally irradiated mice with Em-Myc hematopoietic stem cells transduced with Trp53 shRNAs 30 . To test whether shRNA expression from a germline TRE-p53.1224 transgene was similarly functional, we generated 'triple transgenic' Em-Myc/Em-tTA/TREp53.1224 mice. Previous studies have shown that tet-regulated Myc overexpression driven by the Em-tTA transgene (Em-SRa control element) causes an immature T cell disease 31 Em-Myc transgene (Em-VH control element). Despite this, we predicted that Trp53 knockdown and Myc overexpression would overlap in a subset of hematopoietic cells of Em-Myc/Em-tTA/TRE-p53.1224 mice and that these animals would more rapidly develop lymphoma. Indeed, the latency of tumorigenesis in Em-Myc/Em-tTA/TREp53.1224 mice compared with their collective Em-Myc single and double-transgenic littermates was significantly reduced (Fig. 6a) . Tumor latency was similar for the three control genotypes: Em-Myc alone, Em-Myc/Em-tTA double-transgenic and Em-Myc/TRE-p53.1224 double-transgenic ( Supplementary Fig. 4 online), suggesting that shRNA expression from the TRE-p53.l224 transgene is tTA dependent and not leaky. In contrast to the canonical grossly enlarged lymph nodes observed in their Em-Myc littermates 27 (Fig. 6b) , many triple transgenic mice became moribund without a large peripheral tumor burden ( Fig. 6b and Table 1 ). Of nine triple-transgenic mice that succumbed with relatively small peripheral lymph nodes, six also had partial hind leg paralysis. This phenotype has previously been associated with lymphoma in mice 32 , although it is infrequently observed in control Em-Myc single-or double-transgenic mice. In principle, these distinct phenotypes could result from the coexpression of Myc and the p53.1224 shRNA in a particular B cell type targeted by both the Em-VH and Em-SRa control elements or from a specific hypomorphic state produced by incomplete suppression of Trp53, as has been described 30 .
Moribund triple-transgenic mice with relatively small peripheral lymph nodes also showed a grossly enlarged spleen taken over by B220 + IgM -(pre-B) tumor cells ( Fig. 6c and Table 1) , with lymphoma dissemination into the lymph nodes and liver (Fig. 6c) . Of nine such Em-Myc/Em-tTA/TRE-p53.1224 mice examined, all except one had highly abundant p53.1224 siRNA in spleen and lymph nodes (Fig. 6d and Table 1 ). We made similar observations in triple-transgenic mice harboring the TRE-p53.1224 line D transgene ( Supplementary Fig. 5  online) . Notably, we did not observe any change in the endogenous microRNA miR-143 (Fig. 6d) , suggesting that expression of the p53.1224 shRNA was not disrupting natural pre-microRNA processing. We did not detect p53.1224 expression in whole spleen of Em-tTA/TRE-p53.1224 double-transgenic mice ( Supplementary Fig. 6 online), presumably because expression from the Em promoter is highest in active B cells that are present only at low levels in normal spleen. Notably, p53.1224 siRNA was present in diseased Em-Myc/ Em-tTA/TRE-p53.1224 spleens at levels known to promote Trp53 knockdown and tumor progression in other contexts 20 (Fig. 6d,e) . Thus, Trp53 shRNA can be abundantly expressed from a cell typespecific, tet-regulated transgene in vivo, thereby compromising the tumor suppressive functions of Trp53.
To determine whether knockdown of Trp53 was reversible, we examined the biological impact of doxycycline addition in lymphoma-bearing triple-transgenic mice. Initially, three primary Em-Myc/Em-tTA/TRE-p53.1224 mice were treated with doxycycline in their drinking water at the onset of paralysis. Within 2 d, each mouse regained full movement and lived for a further 24, 25 and 64 d, respectively, before tumors eventually relapsed. In contrast, untreated 
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mice progressed to full paralysis within a few days. Magnetic resonance imaging (MRI) of one mouse showed enlarged spleen and lymph nodes at the time of paralysis, which markedly regressed after 7 d of doxycycline treatment (Fig. 7a) . The spleen of the treated mouse also appeared darker by MRI, consistent with tumor cell clearance (Fig. 7a) .
To examine the performance of the tet-regulated system more systematically, we transplanted lymphoma cells harvested from Em-Myc/Em-tTA/TRE-p53.1224 mice into a cohort of immunocompromised mice. Approximately two weeks after tail vein injection, all mice presented with partial hind leg paralysis similar to that observed in many of the primary triple-transgenic mice. If left untreated, these animals progressed to complete paralysis in a few days and had to be killed (Fig. 7b) . Consistent with observations in primary tripletransgenic mice, untreated transplant recipients had massive spleen enlargement owing to lymphoma cell infiltration (Fig. 7c) , with abundant p53.1224 siRNA expression in whole spleen and lymph nodes (Fig. 7d) . Similarly, after just 2 d of doxycycline treatment, the paralysis resolved, and we observed a marked change in spleen histopathology, including substantial lymphoma cell clearance and partial restoration of normal tissue architecture (Fig. 7c) . Doxycycline treatment abolished p53.1224 siRNA expression in the spleen (Fig. 7e) and produced a marked increase in cells expressing high levels of Trp53 or undergoing apoptosis (Fig. 7c) . These results are consistent with observations in cultured primary Em-Myc/Em-tTA/TRE-p53.1224 lymphoma cells, which lose p53.1224 siRNA expression, show restored Trp53 expression and undergo massive apoptosis within 2 d of doxycycline treatment ( Supplementary Fig. 7 online) . Notably, the lymphoma regression and apoptosis we observed were due to Trp53 reactivation and were not a result of doxycycline toxicity, as mice bearing triple-transgenic lymphomas transduced with a constitutive Trp53 shRNA showed only a minimal increase in survival and retained Trp53 siRNA production after doxycycline treatment (Fig. 7b,e) .
Together, these data suggest that ongoing Trp53 knockdown in established lymphomas is required for their survival and progression.
Although all tumors derived from triple-transgenic animals underwent massive involution in response to doxycycline treatment, they invariably relapsed within several weeks, often with enlarged lymph nodes reminiscent of control Em-Myc transgenic mice (Fig. 7b and  data not shown) . In most relapsed lymphomas derived from tripletransgenic animals (1/2 primary and 6/7 transplanted), the p53.1224 siRNA was barely detectable or absent, implying that these lymphomas eventually escape their dependence on Trp53 knockdown through additional genetic alterations, consistent with a previous report 33 . However, one relapsed lymphoma arising in a primary triple-transgenic animal showed high amounts of the p53.1224 siRNA (data not shown), perhaps reflecting changes that allow constitutive activation of the TRE-p53.1224 transgene, as has been reported in some tet-regulated oncogene models upon tumor relapse 34 . Nevertheless, the potent biological effects we observe in tumorigenesis and upon relapse highlight the power of conditional RNA interference technology for studying biological phenomena in transgenic mice and point to its utility for probing molecules and pathways that are potential candidates for drug development.
DISCUSSION
By adapting a tet-responsive system previously used for conditional cDNA overexpression and synthetic microRNAs capable of silencing a gene of interest, we demonstrate a rapid and simple method for generating transgenic mice with tissue-specific and reversible RNAimediated inhibition of endogenous gene expression. We have shown that standard transgenic techniques can introduce a tet-regulatable shRNA expression cassette into the mouse genome, where it remains latent until mice are crossed with existing transgenic tet transactivator mouse lines. These double-transgenic mice produce shRNA and endogenous gene knockdown in a tissue-specific manner that can be regulated by doxycycline in the drinking water. Using this system to knock down Trp53, we were able to regulate endogenous Trp53 expression in a tissue-specific, conditional, reversible manner, producing profound biological phenotypes in an entirely transgenic setting.
In developing this approach, we were concerned that the levels of tet transactivator produced in existing mouse strains would be insufficient to drive functional shRNA expression or, alternatively, that overexpression of the exogenous microRNA would saturate the RNAi machinery leading to off-target effects as has recently been described in an experimental gene therapy setting 35 . However, we observed abundant p53.1224 siRNA production and Trp53 protein knockdown in multiple tissue types of TRE-p53.1224 mice when we crossed them with the general tet-on CMV-rtTA mouse strain and in the liver and pre-B cell Em-Myc lymphomas when we crossed them with the tissue-specific tet-off strains LAP-tTA and Em-tTA, respectively. In some cases, p53.1224 siRNA was produced in equivalent amounts as observed in tumors resulting from retroviral p53.1224 expression, in which selection for maximal Trp53 knockdown has probably occurred 20 . Moreover, we showed that Trp53 shRNA production by either Em-tTA or LAP-tTA in vivo does not interfere with endogenous microRNA maturation. Although not all tet-transactivator mouse lines may be useful for gene knockdown, it seems that tetregulated shRNA production can effectively harness but not saturate the endogenous RNAi machinery in vivo, potentially affording it a similar experimental versatility as tet-regulated cDNA overexpression but allowing regulation of endogenous gene expression.
We chose to target the Trp53 tumor suppressor gene as a proof of principle, as the gene is well characterized in vitro and in vivo. In addition, by addressing whether Trp53 loss was required for the continued progression of tumors in vivo, we could assess the utility of regulated RNAi knockdown to validate a pathway that is a potential target for new therapies. Using our ability to conditionally regulate endogenous Trp53 expression in vivo, we show that Em-Myc lymphomas invariably respond to Trp53 reactivation through apoptosis and tumor involution, although these tumors eventually relapse. Extension of survival by 64 d in one mouse suggests complete tumor clearance upon Trp53 restoration, with relapse potentially due to de novo Em-Myc lymphomagenesis. Our results are generally consistent with recent studies from our group and other groups 33,36,37 using different approaches and tumor types, highlighting the potential of therapies that reactivate Trp53 but also pointing toward the potential for resistance. Although other strategies have proved effective for conditionally regulating Trp53, they do not allow reversible regulation of Trp53 in a tissue-specific fashion. More notably, the system described herein should be readily portable to any other gene.
As many tet-transactivator transgenic mouse strains are available, the conditional RNAi approach described here holds promise as a general method for controlling endogenous gene expression in vivo. The pronuclear injection transgenesis strategy we used is rapid and simple, although variations on this strategy such as targeted knock-ins or BAC transgenics may increase the frequency of founder animals capable of effective gene knockdown. Furthermore, microRNA-based shRNAs efficiently silence gene expression when expressed in the 3¢ UTR of protein-coding cDNAs 21 , which should allow coregulation of a protein-coding cDNA and shRNA of interest from the same transcript or incorporation of a green fluorescent protein (GFP) or bioluminescence reporter to monitor shRNA production in vivo. Although tet-regulated RNAi does not produce the null genotype achievable with Cre/loxP-based strategies, its reversibility and ability to produce hypomorphic phenotypes opens up new experimental possibilities. For example, as illustrated here, it should be possible to study the action of any endogenous gene in tumor maintenance. These include testing potential drug targets in mouse models of cancer, as RNAi probably mimics drug action more faithfully than complete gene disruption, and, like drug administration, its effects can be rapidly reversed. Other potential uses involve assessing the spatial or temporal requirement for endogenous genes during development. Therefore, in principle, the strategy described here may allow more effective use of mice as vehicles for understanding gene function and as preclinical models of human disease.
METHODS
Transgenic mice. A 948-bp transgene fragment was excised from the TMPp53.1224 vector 20 using BglII and AgeI. Transgenic mice were generated by standard pronuclear injection procedures. Founder line A (mainly used in this study) was generated on a C57BL/6;SJL F1 background and subsequently backcrossed onto C57BL/6. Founder line D was generated on an FVB/N background. Mice were genotyped by PCR using the primers miR30fwd and TREmiR30genoR (Supplementary Table 1 online), yielding a 300-bp product. Other mouse lines used were Em-Myc 27 , LAP-tTA 9 , Em-tTA 31 , Rosa26-M2rtTA 11 and CMV-rtTA 23 . Doxycycline (Clontech) was administered to mice at 2 mg ml -1 (4 mg ml -1 for tet-on studies) in a 1% sucrose solution in drinking water. MRI was performed at the Memorial Sloan-Kettering Cancer Center Animal Imaging Facility. The Cold Spring Harbor Animal Care and Use Committee approved all procedures described in this work.
Cell culture and expression analysis. Cell culture, small RNA blotting, and protein blotting were performed as described previously 20 . To test founder lines for Trp53 knockdown, we infected MEFs with pRev-TetOFF-IN (Clontech) and selected in G418 before harvesting. For all Trp53 protein blots in Figure 1 and Figure 2 , MEFs were treated with 0.5 mg ml -1 adriamycin for 4-8 h to induce Trp53. The p53.1224 siRNA blot probe sequence is listed in Supplementary  Table 1 . miR-122 and miR-143 probe sequences were as described previously 25 . Lymphoma immunotypes were assessed by flow cytometry after incubation of cultured lymphoma cells with fluorescently conjugated antibodies recognizing hematopoietic lineage markers. Thymocyte apoptosis assays were performed as described previously 38 . For these experiments, doxycycline was administered in the drinking water of the mouse before harvesting, but not during thymocyte culture.
Adenovirus preparation and in vivo infection. To generate high-titer viral stocks, 2 Â 10 8 HEK293 packaging cells were infected at 5 to 10 plaque-forming units (pfu) per cell (Adeno-Cre, Vector Biolabs). Adenovirus propagation and preparation was performed as described previously 39 . Before infection, virus was dialyzed twice against a solution containing 10 mM Tris (pH 8), 1 mM MgCl 2 and 140 mM NaCl at 4 1C. Infection of the mice was carried out by administration of 0.25 ml virus solution into the tail vein at a total virus load of 5 Â 10 9 viral particles per gram body weight. Ten hours after injection, livers were fixed in OCT compound and stored at -80 1C before sectioning and assessment of Trp53 immunofluorescence.
Note: Supplementary information is available on the Nature Genetics website.
